Related Experiment Video
Updated: Jun 24, 2025
Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Engineered Exosomes Containing microRNA-29b-2 and Targeting the Somatostatin Receptor Reduce Presenilin 1 Expression
En-Yi Lin1,2, Shao-Xi Hsu1, Bing-Hua Wu1
1Department of Life Science and Graduate Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan.
Purpose:
Exosomes are membrane vesicles secreted by various cells and play a crucial role in intercellular communication. They can be excellent delivery vehicles for oligonucleotide drugs, such as microRNAs, due to their high biocompatibility. MicroRNAs have been shown to be more stable when incorporated into exosomes; however, the lack of targeting and immune evasion is still the obstacle to the use of these microRNA-containing nanocarriers in clinical settings. Our goal was to produce functional exosomes loaded with target ligands, immune evasion ligand, and oligonucleotide drug through genetic engineering in order to achieve more precise medical effects.
Methods:
To address the problem, we designed engineered exosomes with exogenous cholecystokinin (CCK) or somatostatin (SST) as the targeting ligand to direct the exosomes to the brain, as well as transduced CD47 proteins to reduce the elimination or phagocytosis of the targeted exosomes. MicroRNA-29b-2 was the tested oligonucleotide drug for delivery because our previous research showed that this type of microRNA was capable of reducing presenilin 1 (PSEN1) gene expression and decreasing the β-amyloid accumulation for Alzheimer's disease (AD) in vitro and in vivo.
Results:
The engineered exosomes, containing miR29b-2 and expressing SST and CD47, were produced by gene-modified dendritic cells and used in the subsequent experiments. In comparison with CD47-CCK exosomes, CD47-SST exosomes showed a more significant increase in delivery efficiency. In addition, CD47-SST exosomes led to a higher delivery level of exosomes to the brains of nude mice when administered intravenously. Moreover, it was found that the miR29b-2-loaded CD47-SST exosomes could effectively reduce PSEN1 in translational levels, which resulted in an inhibition of beta-amyloid oligomers production both in the cell model and in the 3xTg-AD animal model.
Conclusion:
Our results demonstrated the feasibility of the designed engineered exosomes. The application of this exosomal nanocarrier platform can be extended to the delivery of other oligonucleotide drugs to specific tissues for the treatment of diseases while evading the immune system.
Insights
Engineered exosomes carrying microRNA-29b-2 were developed for Alzheimer's disease treatment. These nanocarriers successfully targeted the brain and reduced amyloid-beta accumulation, showing promise for neurological disorder therapies.
Area of Science:
- Biotechnology
- Nanomedicine
- Neuroscience
Background:
- Exosomes are natural nanovesicles crucial for intercellular communication.
- They offer biocompatible delivery for oligonucleotide drugs like microRNAs.
- Challenges include targeting specificity and immune evasion for clinical applications.
Purpose of the Study:
- To engineer exosomes for targeted delivery of microRNA-29b-2.
- To enhance exosome immune evasion for improved therapeutic efficacy.
- To develop a nanocarrier platform for treating Alzheimer's disease.
Main Methods:
- Genetic engineering of exosomes with targeting ligands (cholecystokinin or somatostatin) and immune evasion proteins (CD47).
- Loading of microRNA-29b-2 into engineered exosomes derived from modified dendritic cells.
- In vivo evaluation of exosome biodistribution, targeting efficiency, and therapeutic effect in Alzheimer's disease models.
Main Results:
- Engineered exosomes expressing somatostatin (SST) and CD47 demonstrated superior brain delivery efficiency.
- miR29b-2-loaded CD47-SST exosomes significantly reduced presenilin 1 (PSEN1) expression.
- Inhibition of beta-amyloid oligomer production was observed in both cell and animal models of Alzheimer's disease.
Conclusions:
- The designed engineered exosomes represent a feasible and effective nanocarrier platform.
- This platform enables targeted delivery of oligonucleotide drugs while evading the immune system.
- Potential applications extend to treating various diseases by delivering specific therapeutic agents to target tissues.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:22MicroRNAs